Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.
作者信息
Stokes Jessica, Simpson Richard J, Katsanis Emmanuel
机构信息
Department of Pediatrics, University of Arizona, Tucson, AZ, United States.
Department of Immunobiology, University of Arizona, Tucson, AZ, United States.
出版信息
Front Immunol. 2022 Apr 14;13:887648. doi: 10.3389/fimmu.2022.887648. eCollection 2022.
Abstract
摘要
相似文献
1
Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.
Front Immunol. 2022 Apr 14;13:887648. doi: 10.3389/fimmu.2022.887648. eCollection 2022.
2
Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4 T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.
Front Immunol. 2022 Feb 15;13:796349. doi: 10.3389/fimmu.2022.796349. eCollection 2022.
3
Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Front Immunol. 2019 Nov 29;10:2668. doi: 10.3389/fimmu.2019.02668. eCollection 2019.
4
Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2020 Feb;26(2):230-241. doi: 10.1016/j.bbmt.2019.09.030. Epub 2019 Oct 2.
5
Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
J Clin Invest. 2019 Mar 26;129(6):2357-2373. doi: 10.1172/JCI124218.
6
Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
Exp Hematol. 2023 Jul;123:56-65. doi: 10.1016/j.exphem.2023.04.003. Epub 2023 Apr 23.
7
Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
Hematology. 2024 Dec;29(1):2326384. doi: 10.1080/16078454.2024.2326384. Epub 2024 Apr 10.
8
Donor-derived CD4/CCR7 T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide.
Bone Marrow Transplant. 2019 Oct;54(10):1686-1693. doi: 10.1038/s41409-019-0511-7. Epub 2019 Mar 19.
9
Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
Int J Hematol. 2022 Oct;116(4):465-481. doi: 10.1007/s12185-022-03428-3. Epub 2022 Aug 5.
10
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Biol Blood Marrow Transplant. 2018 Nov;24(11):2259-2264. doi: 10.1016/j.bbmt.2018.07.008. Epub 2018 Aug 7.
引用本文的文献
1
Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial.
Front Immunol. 2025 Apr 9;16:1568862. doi: 10.3389/fimmu.2025.1568862. eCollection 2025.
2
Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies.
Cancer Chemother Pharmacol. 2024 Sep;94(3):361-372. doi: 10.1007/s00280-024-04688-y. Epub 2024 Jun 15.
3
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Front Immunol. 2023 Nov 22;14:1329850. doi: 10.3389/fimmu.2023.1329850. eCollection 2023.
4
Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease.
Front Immunol. 2023 Jan 9;13:1045710. doi: 10.3389/fimmu.2022.1045710. eCollection 2022.
本文引用的文献
1
Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation.
EJHaem. 2020 May 26;1(1):286-292. doi: 10.1002/jha2.20. eCollection 2020 Jul.
2
Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4 T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.
Front Immunol. 2022 Feb 15;13:796349. doi: 10.3389/fimmu.2022.796349. eCollection 2022.
3
Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.
Front Immunol. 2021 Jun 24;12:699128. doi: 10.3389/fimmu.2021.699128. eCollection 2021.
4
Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI149296.
5
Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation.
Cancers (Basel). 2021 Apr 3;13(7):1702. doi: 10.3390/cancers13071702.
6
Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
Transplant Cell Ther. 2021 Jul;27(7):601.e1-601.e7. doi: 10.1016/j.jtct.2021.03.032. Epub 2021 May 7.
7
Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3.
Front Immunol. 2020 Jul 16;11:1410. doi: 10.3389/fimmu.2020.01410. eCollection 2020.
8
Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia.
Oncoimmunology. 2020 Apr 30;9(1):1758011. doi: 10.1080/2162402X.2020.1758011. eCollection 2020.
9
Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2020 Feb;26(2):230-241. doi: 10.1016/j.bbmt.2019.09.030. Epub 2019 Oct 2.
10
Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy.
Open Forum Infect Dis. 2019 May 31;6(7):ofz252. doi: 10.1093/ofid/ofz252. eCollection 2019 Jul.
Zotero 插件